Fibroblast growth factor(FGF)19 subfamily is a recently discovered class of metabolic regulators ,including FGF19,FGF21 and FGF23,which maintain whole-body homeostasis,regulate the balance of bile acids ,regulate glucose and lipid metabolism,and maintain the homeostasis of phosphate/vitamin D.In view of these functions,the FGF19 subfamily can be used as a biomarker for the clinical diagnosis of related metabolic diseases ,including diabetes ,obesity,metabolic disor-ders caused by tumors .The study of analogues and inhibitors is now underway and has entered clinical trials ,proving that it has great potential in the treatment of metabolic diseases .However,the mechanisms of FGF19 subfamily have not yet been fully elucidated ,and its stability and safety need to be further studied in the future .%成纤维细胞生长因子(FGF)19亚家族是新近发现的一类代谢调节因子,包括FGF19、FGF21和FGF23,具有维持全身稳态、调控胆汁酸平衡、调节葡萄糖和脂质代谢、维持磷酸盐/维生素D稳态等作用.鉴于这些功能,FGF19亚家族可作为临床诊断部分相关代谢性疾病的生物标志物,包括糖尿病、肥胖、肿瘤导致的代谢紊乱等.目前正在进行对其类似物、抑制剂的研究,并已进入临床试验阶段,证明FGF19亚家族在治疗相关代谢性疾病方面有很大潜力.但FGF19亚家族的作用机制尚未完全阐明,未来其稳定性和安全性亦需更多研究来证明.
展开▼
